Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies


Clinical study of the safety and efficacy of KTE-X19 in pediatric and adolescent subjects with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) or relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).
Who can enter
  • Children and adolescents with B-precursor acute lymphoblastic leukemia (ALL) or B-cell non-Hodgkin lymphoma (NHL) who did not or insufficiently respond to standard treatment (refractory), or in whom the disease has returned (relapsed).
  • Age ≤21 years (ALL) or <18 years (NHL)


The goal of this study is to determine whether CAR T cells (in this case KTE-X19 CAR T cells made by the company Kite Pharma), given to children after three days of chemotherapy, are safe and effective in the treatment of children with relapsed or refractory ALL or NHL.


The experimental treatment in this study is called KTE-X19.

KTE-X19, made by the company Kite Pharma, is a so-called CAR T-cell therapy (immunotherapy). T cells (a type of white blood cells) are filtered from the patient’s blood and are modified in the laboratory so that they can detect and destroy cancer cells. The modified cells are called ‘chimeric antigen receptor’ (CAR) T cells.

The CAR T cells are returned to the patient via infusion. They can now recognize the protein CD19 that is present on the surface of leukemia and lymphoma cells, and also on normal B cells.

The goal of the treatment with CAR T cells is to achieve remission. There is too little experience to tell whether treatment with CAR T cells alone is sufficient in the long run to cure the leukemia or lymphoma. Therefore, the need for further treatment (e.g. stem cell transplantation) will be examined.

In order to participate in a study please refer to your/your child’s doctor.

Last reviewed

February 21, 2022